Silencing of the constitutive activity of the dopamine D1B receptor. Reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties.
Recently, we have shown that the dopamine D1B/D5 receptor displays binding and coupling properties that are reminiscent of those of the constitutively activated G protein-coupled receptors when compared with the related D1A/D1 receptor subtype (Tiberi, M., and Caron, M. G. (1994) J. Biol. Chem. 269, 27925-27931). The carboxyl-terminal region of the third cytoplasmic loop of several G protein-coupled receptors has been demonstrated to be important for the regulation of the equilibrium between inactive and active receptor conformations. In this cytoplasmic region, the primary structure of dopamine D1A and D1B receptors differs by only two residues: Phe264/Arg266 are present in D1A receptor compared with Ile288/Lys290 in the D1B receptor. To investigate whether these structural differences could account for the distinct binding and coupling properties of these dopamine receptor subtypes, we swapped the variant residues located in the carboxyl-terminal region by site-directed mutagenesis. The exchange of the D1A receptor residue Phe264 by the D1B receptor counterpart isoleucine led to a D1A receptor mutant exhibiting D1B-like constitutive properties. In contrast, substitution of D1B receptor Ile288 by the D1A receptor counterpart phenylalanine resulted in a loss of constitutive activation of the D1B receptor with binding and coupling properties similar to the D1A receptor. The Arg/Lys substitution had no effect on the function of either receptor. These results demonstrate that the carboxyl-terminal region, and in particular residue Ile288, is a major determinant of the constitutive activity of the dopamine D1B receptor. Moreover, these results establish that not only can agonist-independent activity of a receptor be induced, but when given the appropriate mutation, it can be reversed or silenced.
Howard Hughes Medical Institute Laboratories, Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710, USA.
S
S
Charpentier
K R
KR
Jarvie
D M
DM
Severynse
M G
MG
Caron
M
M
Tiberi
D000262:Adenylyl Cyclases / Q000378:metabolism; D001120:Arginine; D001552:Benzazepines / Q000031:analogs & derivatives / Q000378:metabolism; D001667:Binding, Competitive; D002069:Butaclamol / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D004298:Dopamine / Q000008:administration & dosage / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007532:Isoleucine; D008958:Models, Molecular; D010649:Phenylalanine; D011487:Protein Conformation; D017447:Receptors, Dopamine D1 / Q000235:genetics / Q000378:metabolism*; D050641:Receptors, Dopamine D5; D013329:Structure-Activity Relationship
C049558:8-iodo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-ol; D001552:Benzazepines; C493605:DRD5 protein, human; D017447:Receptors, Dopamine D1; D007532:Isoleucine; D050641:Receptors, Dopamine D5; D010649:Phenylalanine; D001120:Arginine; D002069:Butaclamol; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D004298:Dopamine